(MENAFN) The US Food and Drug Administration (FDA) has given two South Korean cosmetics makers and one pharmaceutical company a warning for their violation of proper manufacturing procedures.
The FDA wrote on its site that the US food anf drug regulator has issued warning letters to Cosmecca Korea Co., It'S Hanbul Co. and pharmaceutical giant Celltrion for their violations of current good manufacturing practice (CGMP) regulations.
The warning letter sent to Cosmecca Korea in February said: "Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act."
According to the US regulator, failure to correct these violations may also result in its continuing to refuse admission of articles manufactured at the plant into the US.
MENAFN2904201800450000ID1096785982
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.